MINNEAPOLIS, MN, US, Nov. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the American Association Equine Practitioners (“AAEP”) conference to be held November 29^th to December 2^nd, 2023 at the San Diego Convention Center in San Diego, California.

PetVivo will exhibit its lead product, SPRYNG^™ with OsteoCushion^™ Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis. The AAEP is the largest veterinary equine conference that services the United States, and normally plays host to more than 5,000 participants including many of the top industry professionals.

“The AAEP provides us the perfect venue to network with the leaders and innovators in the equine industry,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This event allows us the opportunity to forge long-lasting relationships with veterinarians, which helps to drive forward our innovative veterinary medical device, SPRYNG with OsteoCushion Technology. We believe the administration of SPRYNG provides a viable option in the management of lameness and other joint related affliction, thereby enhancing the lives of horses, as well as other companion animals.”

Furthermore, Tom Yarbrough, DVM, ACVS, the Director of Product Research for PetVivo Holdings Inc., is providing a presentation entitled “Modern Wild West: Navigating the new classes of joint therapeutics”. In addition, Joseph Manning, DVM, MBA, Senior Technical Veterinarian for PetVivo Holdings, inc., will be discussing the use of Spryng^™ with OsteoCushion^™ Technology in a presentation entitled “Advancements in Intra-Articular Therapies: Experiences with a novel collagen-elastin hydrogel microparticles (CEHM) biomaterial used intra-articularly for joint conditions in equines”. If you would like to attend the presentations by Dr. Yarbrough and Dr. Manning the details are provided below.

Conference Exhibit Details:

American Association of Equine Practitioners Conference (AAEP)

Booth #: 1023

Dates:

Thursday, November 30: 10:00 a.m. - 6:00 p.m.

Friday, December 1: 10:00 a.m. - 6:00 p.m.

Saturday, December 2: 10:00 a.m. - 4:00 p.m.

Location: San Diego Convention Center in San Diego, California

Dr. Thomas Yarbrough Presentation Schedule:

Presentation Title: Modern Wild West: Navigating the new classes of joint therapeutics

Presentation Date: Friday, December 1: 11:00 a.m. - 11:30 a.m.

Location for Presentation 1: San Diego Convention Center: Theater 2

Dr. Joseph Manning Presentation Schedule:

Presentation Title: Advancements in Intra-Articular Therapies: Experiences with a novel collagen-elastin hydrogel microparticles (CEHM) biomaterial used intra-articularly for joint conditions in equines

Presentation Date: Thursday, November 30: 11:00 a.m. - 11:30 a.m.

Location for Presentation 2: San Diego Convention Center: Theater 2

For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or visit https://petvivo.com/ and https://sprynghealth.com/.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG^™ with OsteoCushion^™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
(952) 405-6216

Forward-Looking Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.